{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:03:44Z","timestamp":1773317024525,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570118"],"award-info":[{"award-number":["81570118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570112"],"award-info":[{"award-number":["81570112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Committee of Shanghai","award":["15401901800"],"award-info":[{"award-number":["15401901800"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.leukres.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T03:46:14Z","timestamp":1510371974000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"64","author":[{"given":"Hu","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2017.11.007_bib0005","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.leukres.2017.11.007_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.leukres.2017.11.007_bib0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2017.11.007_bib0020","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2017.11.007_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2017.11.007_bib0030","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2017.11.007_bib0035","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML?","volume":"126","author":"Larson","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.11.007_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2017.11.007_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.leukres.2017.11.007_bib0050","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.11.007_bib0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2015-12-685149","article-title":"BCR-ABL1 mutation not equal ponatinib resistance","volume":"127","author":"Saglio","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.11.007_bib0060","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2017.11.007_bib0065","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-08-0492","article-title":"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies","volume":"7","author":"Zabludoff","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.leukres.2017.11.007_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.leukres.2017.11.007_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0473-1","article-title":"Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine","volume":"36","author":"Isono","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2017.11.007_bib0080","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/cc.9.5.10935","article-title":"Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase","volume":"9","author":"McNeely","year":"2010","journal-title":"ABBV Cell Cycle"},{"issue":"4","key":"10.1016\/j.leukres.2017.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.leukres.2017.11.007_bib0090","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-09-3277","article-title":"In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762","volume":"16","author":"Mitchell","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2017.11.007_bib0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.leukres.2017.11.007_bib0100","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1535-7163.MCT-12-0902","article-title":"The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair","volume":"12","author":"Dai","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2017.11.007_bib0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/1471-2407-13-604","article-title":"Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo","volume":"13","author":"Montano","year":"2013","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2017.11.007_bib0110","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.11.007_bib0115","doi-asserted-by":"crossref","first-page":"40778","DOI":"10.1038\/srep40778","article-title":"Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage","volume":"7","author":"Massey","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.leukres.2017.11.007_bib0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1535-6108(04)00056-X","article-title":"BCR\/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint","volume":"5","author":"Dierov","year":"2004","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.leukres.2017.11.007_bib0125","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.leukres.2017.11.007_bib0130","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2017.11.007_bib0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.4161\/auto.7.10.16636","article-title":"PML-RARalpha enhances constitutive autophagic activity through inhibiting the Akt\/mTOR pathway","volume":"7","author":"Huang","year":"2011","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.leukres.2017.11.007_bib0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"18","key":"10.1016\/j.leukres.2017.11.007_bib0145","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2009-10-249623","article-title":"Bag1 directly routes immature BCR-ABL for proteasomal degradation","volume":"116","author":"Tsukahara","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2017.11.007_bib0150","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2010-08-300608","article-title":"Wrapping BCR-ABL: it\u2019s in the bag","volume":"116","author":"Melo","year":"2010","journal-title":"Blood"},{"issue":"4944","key":"10.1016\/j.leukres.2017.11.007_bib0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.leukres.2017.11.007_bib0160","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2017.11.007_bib0165","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2017.11.007_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-6-67","article-title":"Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia","volume":"6","author":"Kaur","year":"2007","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2017.11.007_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program"},{"issue":"17","key":"10.1016\/j.leukres.2017.11.007_bib0180","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMc1007927","article-title":"Second-generation BCR-ABL kinase inhibitors in CML","volume":"363","author":"Akard","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2017.11.007_bib0185","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1073\/pnas.79.9.2942","article-title":"Mechanism by which caffeine potentiates lethality of nitrogen mustard","volume":"79","author":"Lau","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.leukres.2017.11.007_bib0190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0960-9822(99)80486-2","article-title":"Caffeine inhibits the checkpoint kinase ATM","volume":"9","author":"Blasina","year":"1999","journal-title":"Curr. Biol."},{"issue":"17","key":"10.1016\/j.leukres.2017.11.007_bib0195","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2017.11.007_bib0200","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2014.60.0767","article-title":"Will targeting Chk1 have a role in the future of cancer therapy?","volume":"33","author":"Sakurikar","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2017.11.007_bib0205","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2017.11.007_bib0210","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.leukres.2014.08.020","article-title":"Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia","volume":"38","author":"Yuan","year":"2014","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2017.11.007_bib0215","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.breast.2014.02.004","article-title":"Chk1 as a new therapeutic target in triple-negative breast cancer","volume":"23","author":"Albiges","year":"2014","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.leukres.2017.11.007_bib0220","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2015.05.053","article-title":"A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer","volume":"162","author":"Dietlein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2017.11.007_bib0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1476-4598-13-147","article-title":"Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human leukemia and lymphoma cells","volume":"13","author":"Bryant","year":"2014","journal-title":"Mol. Cancer"},{"issue":"6330","key":"10.1016\/j.leukres.2017.11.007_bib0230","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal-An attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.leukres.2017.11.007_bib0235","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.leukres.2017.11.007_bib0240","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Mao","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.leukres.2017.11.007_bib0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.leukres.2017.11.007_bib0250","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Res."},{"issue":"20","key":"10.1016\/j.leukres.2017.11.007_bib0255","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2016.09.041","article-title":"Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand","volume":"26","author":"Demizu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T17:06:56Z","timestamp":1603300016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":51,"alternative-id":["S0145212617305854"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.11.007","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}